0000905148-23-000957.txt : 20230921 0000905148-23-000957.hdr.sgml : 20230921 20230921163001 ACCESSION NUMBER: 0000905148-23-000957 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230919 FILED AS OF DATE: 20230921 DATE AS OF CHANGE: 20230921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOODMAN COREY S CENTRAL INDEX KEY: 0001278411 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41799 FILM NUMBER: 231269404 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Adelman Robert J CENTRAL INDEX KEY: 0001329161 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41799 FILM NUMBER: 231269405 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VENBIO GLOBAL STRATEGIC GP III, L.P. CENTRAL INDEX KEY: 0001869303 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41799 FILM NUMBER: 231269407 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-800-0800 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic Fund III, L.P. CENTRAL INDEX KEY: 0001739920 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41799 FILM NUMBER: 231269408 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VENBIO GLOBAL STRATEGIC GP III, LTD CENTRAL INDEX KEY: 0001869300 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41799 FILM NUMBER: 231269406 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCI STATE: CA ZIP: 94158 BUSINESS PHONE: 415-800-0800 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCI STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RayzeBio, Inc. CENTRAL INDEX KEY: 0001825367 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (619) 937-2754 MAIL ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 form4.xml X0508 4 2023-09-19 true 0001825367 RayzeBio, Inc. RYZB 0001739920 venBio Global Strategic Fund III, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001869303 VENBIO GLOBAL STRATEGIC GP III, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001869300 VENBIO GLOBAL STRATEGIC GP III, LTD 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001329161 Adelman Robert J 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true 0001278411 GOODMAN COREY S 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true false Common Stock 2023-09-19 4 C 0 3786957 A 3786957 D Common Stock 2023-09-19 4 C 0 1123862 A 4910819 D Common Stock 2023-09-19 4 C 0 247343 A 5158162 D Series A Convertible Preferred Stock 2023-09-19 4 C 0 3786957 D Common Stock 3786957 0 D Series B Convertible Preferred Stock 2023-09-19 4 C 0 1123862 D Common Stock 1123862 0 D Series C Convertible Preferred Stock 2023-09-19 4 C 0 216127 D Common Stock 247343 0 D Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date. Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date. Each share of Series C Convertible Preferred Stock (the "Series C Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date. These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein. Dr. Aaron Royston serves as a member of the Issuer's board of directors and is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III. venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21 venBio Global Strategic GP III, L.P., by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 2023-09-21 venBio Global Strategic GP III, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21 Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21 Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact 2023-09-21